Company news
AN2 Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 10, 2023
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 28, 2023
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 8, 2022
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
October 5, 2022
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
September 28, 2022
AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 10, 2022
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
June 28, 2022
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 9, 2022
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
May 8, 2022
AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering
March 23, 2022
Decks
- Investor Presentation (September 2026)
Investor deck · 50 slides · September 2026
- Corporate Update (March 2026)
Corporate update · 17 slides · Mar 4, 2026
- Investor Presentation (June 2025)
Investor deck · 40 slides · Jun 11, 2025